ResMed Inc.
219.95USD
-1.1000 (-0.50%)
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | 4.2B | 4.7B | 5.1B | 5.7B | 5.8B | 6.2B |
| Q1 | 950.3M | 1.1B | 1.2B | 1.3B | 1.4B | — |
| Q2 | 1.0B | 1.2B | 1.3B | 1.4B | 1.5B | — |
| Q3 | 1.1B | 1.2B | 1.3B | 1.4B | — | — |
| Q4 | 1.1B* | 1.2B* | 1.3B* | 1.5B* | — | — |
Revenue
| (USD) | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| FY | 6.09 | 6.92 | 9.51 | 10.43 | 12.08 | 13.21 |
| Q1 | 1.43 | 1.49 | 2.11 | 2.37 | 2.69 | — |
| Q2 | 1.53 | 1.42 | 2.34 | 2.68 | 3.04 | — |
| Q3 | 1.58 | 2.04 | 2.48 | 2.74 | — | — |
| Q4 | 1.56* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| 1.98* |
| 2.58* |
| 2.63* |
| — |
| — |